ReviewMetabolic brain disease2026
Vitamin K in brain metabolism and cognitive function: mechanistic evidence, human associations, and unresolved questions.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin K acts as a critical regulator across diverse biological systems, contributing significantly to skeletal integrity, cardiovascular functions, metabolic homeostasis, and immune defenses. Experimental studies increasingly suggest that it also plays an important role in the nervous system, supporting neuronal growth, differentiation, and survival. Its antioxidant, anti-inflammatory, and antiapoptotic effects, along with its capacity to act as an alternative electron carrier in mitochondria, further indicate potential neuroprotective properties. This narrative review synthesizes evidence from recent cell and animal studies, mechanistic research on sphingolipid metabolism, and observational data evaluating vitamin K status and cognitive outcomes. Findings from populations receiving long-term vitamin K antagonist therapy were reviewed to highlight potential clinical implications. Regulation of sphingolipid pathways by vitamin K appears to support neuronal proliferation and resilience, while adequate vitamin K levels have been associated with better cognitive performance. Conversely, prolonged exposure to vitamin K antagonists has been linked to impairments in visual memory and verbal fluency, as well as reductions in brain volume. Evidence also indicates that vitamin K is essential for the synthesis and maintenance of myelin and neuronal membrane components, and for activating vitamin K-dependent proteins that preserve neuronal integrity. Beyond its established role in coagulation, emerging preclinical and observational evidence suggests that vitamin K may possess neuroprotective potential through molecular, structural, and antioxidant mechanisms. The observed association between vitamin K antagonist therapy and cognitive decline in older adults highlights the need for comprehensive clinical studies to clarify causality, determine therapeutic relevance, and better define the role of vitamin K in brain health.
Indexed as
Identifiers
42635642What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.